Saudi German Health H1 2024 profit rises to SAR 113.1M; Q2 at SAR 61.2M

04/08/2024 Argaam Exclusive

Middle East Healthcare Co. (Saudi German Health) reported a net profit of SAR 113.1 million in H1 2024, compared with SAR 90.4 million in the year-earlier period.



Financials (M)

Item 6m 2023 6m 2024 Change‬
Revenues 1,262.31 1,401.87 11.1 %
Gross Income 454.13 538.92 18.7 %
Operating Income 145.49 223.36 53.5 %
Net Income 90.37 113.11 25.2 %
Average Shares 92.04 92.04 -
EPS (Riyals) 0.98 1.23 25.2 %

This rise was attributed to an increase in patients flow as well as higher number of surgeries and case mix.

 

The company also posted a capital gain of SAR 19.6 million on sale of land in Riyadh.

 

The second-quarter net profit saw a spike of 52% to SAR 61.2 million from SAR 40.25 million in Q2 2023 on higher number of inpatients and outpatients as well as utilization of outpatient clinics and ramping up of new facilities.

 

The healthcare services provider’s Q2 net earnings also rose by 17.8% from SAR 51.94 million in Q1 2024.



Current Quarter Comparison (M)

Compared With The
Item Q2 2023 Q2 2024 Change‬
Revenues 624.33 712.66 14.1 %
Gross Income 228.63 279.07 22.1 %
Operating Income 68.99 105.73 53.3 %
Net Income 40.25 61.17 52.0 %
Average Shares 92.04 92.04 -
EPS (Riyals) 0.44 0.66 52.0 %

Shareholders’ equity, after minority interest, reached SAR 1.63 billion by the end of the six-month period, compared to SAR 1.45 billion a year earlier.

View More Financial Results

 

View other reports

Share Price

Middle East Healthcare Co.
70.10
(0.50) (0.71 %)

Middle East Healthcare Co. (SAUDI GERMAN HEALTH)

More


Financial Ratios
Current
Market Cap (M Riyal) 6,452.00
Enterprise Value (EV) (M) 8,847.51
Shares Outstanding ((M)) 92.04
EPS ( Riyal) (TTM) 2.30
Book Value (BV) ( Riyal) 18.46
Par Value ( Riyal) 10.00
Adjusted P/E (Last12) 33.60
P/E (TTM) 30.53
Price/book 3.80
Return on Average Assets (%) (TTM) 4.2
Return on Average Equity (%) (TTM) 13.2
more


Financial results (Million)

Period Revenues Change Gross Income Change Operating Income Change
Q1 2015 391.64 9.0 % 208.99 4.8 % 102.89 37.0 %
Q2 2015 372.00 7.2 % 203.88 9.7 % 89.24 1.2 %
Q3 2015 352.20 9.0 % 183.23 5.0 % 88.21 23.3 %
Q4 2015 418.69 13.4 % 214.04 12.6 % 97.86 24.9 %
Q1 2016 421.52 7.6 % 216.62 3.7 % 103.68 0.8 %
Q2 2016 410.07 10.2 % 212.49 4.2 % 76.56 (14.2 %)
Q3 2016 379.09 7.6 % 199.40 8.8 % 91.10 3.3 %
Q4 2016 404.96 (3.3 %) 199.88 (6.6 %) 87.04 (11.1 %)
Q1 2017 393.53 (6.6 %) 180.47 (16.7 %) 107.04 3.2 %
Q2 2017 351.28 (14.3 %) 138.63 (34.8 %) 58.97 (23.0 %)
Q3 2017 352.98 (6.9 %) 133.30 (33.1 %) 55.70 (38.9 %)
Q4 2017 364.60 (10.0 %) 145.47 (27.2 %) 73.06 (16.1 %)
Q1 2018 395.11 0.4 % 160.42 (11.1 %) 85.82 (19.8 %)
Q2 2018 346.13 (1.5 %) 116.91 (15.7 %) 31.66 (46.3 %)
Q3 2018 338.77 (4.0 %) 111.87 (16.1 %) 21.29 (61.8 %)
Q4 2018 310.68 (14.8 %) 111.56 (23.3 %) 23.96 (67.2 %)
Q1 2019 350.18 (11.4 %) 101.63 (36.6 %) 18.31 (78.7 %)
Q2 2019 353.20 2.0 % 102.76 (12.1 %) 7.58 (76.0 %)
Q3 2019 386.76 14.2 % 119.96 7.2 % 33.31 56.5 %
Q4 2019 406.51 30.8 % 148.59 33.2 % 44.06 83.9 %
Q1 2020 436.31 24.6 % 146.86 44.5 % 24.36 33.0 %
Q2 2020 373.26 5.7 % 120.49 17.3 % 23.73 212.9 %
Q3 2020 492.13 27.2 % 171.91 43.3 % 42.12 26.4 %
Q4 2020 448.89 10.4 % 139.12 (6.4 %) 17.20 (61.0 %)
Q1 2021 418.37 (4.1 %) 123.16 (16.1 %) (0.04) (100.2 %)
Q2 2021 456.57 22.3 % 152.64 26.7 % 20.12 (15.2 %)
Q3 2021 498.73 1.3 % 172.27 0.2 % 27.46 (34.8 %)
Q4 2021 498.95 11.2 % 160.11 15.1 % (7.03) (140.9 %)
Q1 2022 513.32 22.7 % 165.02 34.0 % 35.28 90551.0 %
Q2 2022 508.09 11.3 % 158.77 4.0 % 21.77 8.2 %
Q3 2022 512.37 2.7 % 152.21 (11.6 %) 26.26 (4.4 %)
Q4 2022 617.96 23.9 % 204.01 27.4 % 57.96 924.3 %
Q1 2023 637.99 24.3 % 225.50 36.6 % 76.51 116.9 %
Q2 2023 624.33 22.9 % 228.63 44.0 % 68.99 216.9 %
Q3 2023 671.05 31.0 % 266.33 75.0 % 109.85 318.4 %
Q4 2023 719.81 16.5 % 293.96 44.1 % 87.15 50.4 %
Q1 2024 689.21 8.0 % 259.86 15.2 % 117.64 53.8 %
Q2 2024 712.66 14.1 % 279.07 22.1 % 105.73 53.3 %


Profit Performance (Million)

Period Net Income Change EPS(Riyal) Extraordinary Income/Expense Net Profit Before Unusual Items EPS Before XO Items
Q1 2015 105.39 31.5 % 1.15 - 105.39 1.15
Q2 2015 91.79 (1.1 %) 1.00 - 91.79 1.00
Q3 2015 90.75 22.0 % 0.99 - 90.75 0.99
Q4 2015 102.32 20.9 % 1.11 - 102.32 1.11
Q1 2016 104.20 (1.1 %) 1.13 - 104.20 1.13
Q2 2016 74.07 (19.3 %) 0.80 - 74.07 0.80
Q3 2016 99.64 9.8 % 1.08 - 99.64 1.08
Q4 2016 84.73 (17.2 %) 0.92 - 84.73 0.92
Q1 2017 109.97 5.5 % 1.19 - 109.97 1.19
Q2 2017 61.95 (16.4 %) 0.67 - 61.95 0.67
Q3 2017 64.88 (34.9 %) 0.70 - 64.88 0.70
Q4 2017 82.69 (2.4 %) 0.90 - 82.69 0.90
Q1 2018 87.13 (20.8 %) 0.95 - 87.13 0.95
Q2 2018 34.27 (44.7 %) 0.37 - 34.27 0.37
Q3 2018 20.16 (68.9 %) 0.22 - 20.16 0.22
Q4 2018 30.69 (62.9 %) 0.33 - 30.69 0.33
Q1 2019 14.59 (83.3 %) 0.16 - 14.59 0.16
Q2 2019 12.28 (64.2 %) 0.13 - 12.28 0.13
Q3 2019 33.23 64.8 % 0.36 - 33.23 0.36
Q4 2019 37.47 22.1 % 0.41 (8.00) 45.47 0.49
Q1 2020 21.18 45.2 % 0.23 - 21.18 0.23
Q2 2020 16.35 33.2 % 0.18 - 16.35 0.18
Q3 2020 34.91 5.1 % 0.38 - 34.91 0.38
Q4 2020 9.54 (74.5 %) 0.10 - 9.54 0.10
Q1 2021 12.10 (42.9 %) 0.13 17.53 (5.43) (0.06)
Q2 2021 9.14 (44.1 %) 0.10 (0.48) 9.62 0.10
Q3 2021 14.35 (58.9 %) 0.16 (4.16) 18.51 0.20
Q4 2021 (18.39) (292.8 %) (0.20) 0.84 (19.24) (0.21)
Q1 2022 20.49 69.3 % 0.22 - 20.49 0.22
Q2 2022 10.43 14.1 % 0.11 - 10.43 0.11
Q3 2022 11.11 (22.6 %) 0.12 - 11.11 0.12
Q4 2022 33.16 280.3 % 0.36 - 33.16 0.36
Q1 2023 50.12 144.6 % 0.54 - 50.12 0.54
Q2 2023 40.25 286.0 % 0.44 - 40.25 0.44
Q3 2023 53.30 379.9 % 0.58 - 53.30 0.58
Q4 2023 36.50 10.1 % 0.40 - 36.50 0.40
Q1 2024 51.94 3.6 % 0.56 - 51.94 0.56
Q2 2024 61.17 52.0 % 0.66 19.37 41.81 0.45

Profitability

Period Gross Margin OIBDA Margin Net Margin Before Unusual Items
Q1 2015 53.05 % 27.10 % 24.96 %
Q2 2015 53.39 % 26.84 % 24.46 %
Q3 2015 52.93 % 27.56 % 25.09 %
Q4 2015 52.79 % 28.05 % 25.43 %
Q1 2016 52.27 % 27.77 % 24.87 %
Q2 2016 51.57 % 26.50 % 23.17 %
Q3 2016 51.71 % 26.41 % 23.34 %
Q4 2016 51.27 % 26.12 % 22.45 %
Q1 2017 49.90 % 26.91 % 23.20 %
Q2 2017 46.99 % 27.02 % 23.30 %
Q3 2017 43.41 % 25.39 % 21.40 %
Q4 2017 40.88 % 25.40 % 21.85 %
Q1 2018 39.47 % 24.17 % 20.26 %
Q2 2018 38.12 % 22.54 % 18.44 %
Q3 2018 37.01 % 20.57 % 15.52 %
Q4 2018 36.01 % 18.10 % 12.39 %
Q1 2019 32.84 % 13.74 % 7.41 %
Q2 2019 31.62 % 12.25 % 5.74 %
Q3 2019 31.12 % 12.85 % 6.48 %
Q4 2019 31.60 % 13.48 % 7.05 %
Q1 2020 32.74 % 13.41 % 7.09 %
Q2 2020 33.43 % 14.66 % 7.25 %
Q3 2020 34.41 % 14.80 % 6.90 %
Q4 2020 33.04 % 13.40 % 4.68 %
Q1 2021 32.01 % 12.65 % 3.20 %
Q2 2021 32.32 % 11.91 % 2.68 %
Q3 2021 32.22 % 11.12 % 1.77 %
Q4 2021 32.48 % 9.71 % 0.18 %
Q1 2022 33.04 % 10.93 % 1.49 %
Q2 2022 32.50 % 10.71 % 1.50 %
Q3 2022 31.29 % 10.75 % 1.12 %
Q4 2022 31.60 % 13.35 % 3.49 %
Q1 2023 32.53 % 15.00 % 4.60 %
Q2 2023 33.87 % 16.89 % 5.63 %
Q3 2023 36.23 % 19.39 % 6.93 %
Q4 2023 38.23 % 20.06 % 6.79 %
Q1 2024 38.78 % 21.40 % 6.73 %
Q2 2024 39.36 % 22.20 % 6.57 %


Per Share Data (Riyal)

Compared With The
Period Shares Outstanding (M) EPS (Riyal) Adjusted EPS (Riyal) Book Value (BV)
Q1 2015 92.04 3.88 3.88 13.50
Q2 2015 92.04 3.87 3.87 12.67
Q3 2015 92.04 4.05 4.05 13.63
Q4 2015 92.04 4.24 4.24 14.70
Q1 2016 92.04 4.23 4.23 16.39
Q2 2016 92.04 4.03 4.03 15.20
Q3 2016 92.04 4.13 4.13 16.43
Q4 2016 92.04 3.94 3.94 17.32
Q1 2017 92.04 4.00 4.00 18.46
Q2 2017 92.04 3.87 3.87 17.09
Q3 2017 92.04 3.49 3.49 17.74
Q4 2017 92.04 3.47 3.47 15.75
Q1 2018 92.04 3.22 3.22 16.69
Q2 2018 92.04 2.92 2.92 15.07
Q3 2018 92.04 2.44 2.44 15.29
Q4 2018 92.04 1.87 1.87 15.71
Q1 2019 92.04 1.08 1.08 15.87
Q2 2019 92.04 0.84 0.84 16.00
Q3 2019 92.04 0.99 0.99 16.36
Q4 2019 92.04 1.06 1.15 16.54
Q1 2020 92.04 1.13 1.22 16.77
Q2 2020 92.04 1.18 1.26 16.95
Q3 2020 92.04 1.19 1.28 17.33
Q4 2020 92.04 0.89 0.89 13.38
Q1 2021 92.04 0.79 0.60 13.51
Q2 2021 92.04 0.71 0.53 13.61
Q3 2021 92.04 0.49 0.35 13.77
Q4 2021 92.04 0.19 0.04 13.66
Q1 2022 92.04 0.28 0.32 13.89
Q2 2022 92.04 0.29 0.33 13.92
Q3 2022 92.04 0.26 0.25 14.04
Q4 2022 92.04 0.82 0.82 14.83
Q1 2023 92.04 1.14 1.14 15.37
Q2 2023 92.04 1.46 1.46 15.82
Q3 2023 92.04 1.92 1.92 16.41
Q4 2023 92.04 1.96 1.96 16.50
Q1 2024 92.04 1.98 1.98 17.08
Q2 2024 92.04 2.20 1.99 17.78

Multiple Ratios (End of Period Price)

Compared With The
Period P/E Adjusted P/E Price/book
Q1 2015 - - -
Q2 2015 - - -
Q3 2015 - - -
Q4 2015 - - -
Q1 2016 17.17 17.17 4.43
Q2 2016 17.16 17.16 4.56
Q3 2016 12.41 12.41 3.12
Q4 2016 18.62 18.62 4.23
Q1 2017 18.48 18.48 4.01
Q2 2017 19.45 19.45 4.41
Q3 2017 17.98 17.98 3.54
Q4 2017 15.52 15.52 3.42
Q1 2018 17.90 17.90 3.46
Q2 2018 20.02 20.02 3.88
Q3 2018 15.00 15.00 2.39
Q4 2018 17.34 17.34 2.07
Q1 2019 29.49 29.49 2.01
Q2 2019 32.63 32.63 1.72
Q3 2019 26.36 26.36 1.59
Q4 2019 28.02 25.89 1.80
Q1 2020 22.49 20.89 1.52
Q2 2020 25.77 23.99 1.79
Q3 2020 30.69 28.61 2.11
Q4 2020 39.35 39.35 2.62
Q1 2021 44.44 58.50 2.60
Q2 2021 54.85 74.08 2.88
Q3 2021 77.28 More than 100 2.75
Q4 2021 More than 100 More than 100 2.32
Q1 2022 More than 100 More than 100 2.34
Q2 2022 More than 100 98.17 2.31
Q3 2022 More than 100 More than 100 1.94
Q4 2022 31.16 31.16 1.72
Q1 2023 33.06 33.06 2.45
Q2 2023 48.33 48.33 4.47
Q3 2023 28.68 28.68 3.36
Q4 2023 45.11 45.11 5.35
Q1 2024 50.07 50.07 5.80
Q2 2024 39.73 43.93 4.93

Business Segments (Million)

Compared With The
Period Inpatient clinics Outpatient clinics Pharmacy Sales Others
Q1 2015 224.99 91.95 70.24 4.46
Q2 2015 211.41 86.64 70.30 3.65
Q3 2015 200.38 85.53 63.54 2.76
Q4 2015 220.47 119.55 72.94 5.72
Q1 2016 241.22 100.20 73.04 7.06
Q2 2016 229.99 99.85 72.93 7.31
Q3 2016 224.32 89.88 62.16 2.72
Q4 2016 220.91 107.73 72.64 3.69
Q1 2017 242.80 104.89 71.94 4.27
Q2 2017 224.48 92.89 70.77 3.54
Q3 2017 133.39 85.39 60.16 3.27
Q4 2017 172.44 114.51 71.35 6.30
Q1 2018 214.32 109.10 68.50 3.20
Q2 2018 188.62 79.63 76.10 1.78
Q3 2018 184.16 98.93 53.64 2.04
Q4 2018 147.36 97.71 61.91 3.70
Q1 2019 181.07 97.28 67.29 4.54
Q2 2019 185.66 95.13 68.96 3.44
Q3 2019 223.51 95.92 64.81 2.51
Q4 2019 222.02 111.18 69.80 3.51
Q1 2020 264.27 98.09 71.34 2.60
Q2 2020 238.16 70.59 61.71 2.81
Q3 2020 301.73 111.20 76.35 2.85
Q4 2020 281.15 110.99 74.56 3.81
Q1 2021 236.94 115.00 61.88 4.54
Q2 2021 284.69 102.17 67.31 2.40
Q3 2021 292.19 139.00 61.71 5.83
Q4 2021 284.48 135.06 74.52 4.89
Q1 2022 290.29 141.03 78.90 3.10
Q2 2022 294.67 138.11 73.11 2.20
Q3 2022 293.31 145.39 71.94 1.74
Q4 2022 360.72 163.35 89.59 4.30
Q1 2023 369.08 176.60 90.42 1.88
Q2 2023 366.84 172.86 76.94 7.70
Q3 2023 404.17 180.18 89.81 (3.12)
Q4 2023 405.24 210.55 103.89 0.13
Q1 2024 393.57 205.97 89.67 -
Q2 2024 408.47 202.81 98.26 3.12

Analysts Estimates (Million)

Item Q2 2024 (e) Q2 2024 (a) Change‬
Average 42.93 61.17 42.48 %

Estimates vs Actual (Million)

Item Q2 2024 (e) Q2 2024 (a) Change
SNB Capital 53.30 61.17 14.8 %
OSOOL AND BAKHEET 47.90 61.17 27.7 %
Hermes 46.00 61.17 33.0 %
Al Rajhi Capital 39.00 61.17 56.8 %
AlJazira Capital 36.40 61.17 68.1 %
United Securities Company 35.00 61.17 74.8 %

Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
loader Train
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Popular Links

Quick Links

Join Us

Argaam.com Copyright © 2024, Argaam Investment, All Rights Reserved
Call Request